Barinthus Biotherapeutics (NASDAQ:BRNS) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Barinthus Biotherapeutics (NASDAQ:BRNS) released its quarterly earnings data on Thursday. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.02, FiscalAI reports.

Barinthus Biotherapeutics Stock Performance

Shares of BRNS stock traded up $0.03 on Friday, reaching $0.60. The stock had a trading volume of 34,881 shares, compared to its average volume of 40,767. The stock has a market cap of $24.47 million, a P/E ratio of -0.58 and a beta of -0.39. Barinthus Biotherapeutics has a 1 year low of $0.51 and a 1 year high of $1.83. The company has a 50 day simple moving average of $0.64 and a 200 day simple moving average of $0.64.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised shares of Barinthus Biotherapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 21st. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Barinthus Biotherapeutics currently has an average rating of “Hold” and an average price target of $4.00.

Institutional Trading of Barinthus Biotherapeutics

An institutional investor recently raised its stake in Barinthus Biotherapeutics stock. Baird Financial Group Inc. raised its position in Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) by 108.2% during the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 192,461 shares of the company’s stock after acquiring an additional 100,000 shares during the quarter. Baird Financial Group Inc. owned approximately 0.48% of Barinthus Biotherapeutics worth $179,000 at the end of the most recent quarter. 25.20% of the stock is owned by hedge funds and other institutional investors.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.